Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies

Solanki, Abhishek A.; Bossi, Alberto; Efstathiou, Jason A.; Lock, Derrick; Mondini, Michele; Ramapriyan, Rishab; Welsh, James W.; Kang, Josephine

doi:10.1016/j.euo.2018.09.013

Cited by 31 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, results showed that Tregs are more sensitive to high radiation dose. It determined that combining immunotherapy by inhibiting of Tregs activity with radiotherapy provided an improved treatment for BLCA rather than single low radiation dose [37]. Our data further showed the TIICs fraction proportion in patients with different radiotherapy sites.…”

Section: Discussionsupporting

confidence: 53%

Immune Cell Infiltration in Bladder Cancer

Liu

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Bladder cancer is one of the most common malignant diseases with high recurrence rates worldwide. Although immunotherapy has been applied in bladder cancer for a long period of time, the tumor-infiltrating immune cells (TIICs) in bladder cancer has not been systematical investigated. Methods CIBERSORT, a versatile computational method for quantifying cell fractions from bulk tissue gene expression profiles (GEPs), was applied to calculate the TIICs fraction proportion in normal bladder tissues and in bladder cancer tissues with the TCGA data. Results compared to normal bladder tissue, B cells naïve, T cells CD4 memory resting and Mast cells resting fractions proportion decreased, and NK resting, macrophages M0 and macrophages M1 increased. In BLCAs tissue, pro-tumorigenic related immune cells were negatively correlated with anti-tumor immune cells. New tumor with locoregional had high fraction proportion of macrophages M0 and macrophages M1. Dendritic cells activated, Monocytes, macrophages M1, Tregs and T cells follicular helper significantly increased in low grade BLCAs. Tregs had a high proportion in BLCAs patients accepted low radiation dose. Conclusions This study indicates that macrophages M2 and Tregs could be the promising immunotherapy targets combined radiotherapy in BLCAs. The result provides valuable information to understand the immunity status in BLCAs.

show abstract

Section: Discussionsupporting

confidence: 53%

Immune Cell Infiltration in Bladder Cancer

Liu

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Therefore, a comprehensive understanding of treatment induced ICD events is critical for the design of rationalistic ICB combinations 28, 29 . While radiation is the most potent ICD inducing therapy, chemotherapeutic agents such as anthracyclines, platinum, taxanes and other agents promote variable degrees of ICD events that ultimately alter tumour immunogenicity 30, 31 . Along this notion, it can be speculated that inflamed tumours with high pre-existing activated TILs and IFN gene expression will produce a higher magnitude of immune-mediated responses compared to non-inflamed tumours given the proximity of intra-tumourally located TILs.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer

Nersesian

Shakfa

Peterson

et al. 2019

Preprint

View full text Add to dashboard Cite

Short title: Adding a little STING to chemotherapies in high grade serous ovarian carcinoma: 16 doxorubicin vs carboplatin 17 25overall survival compared to their carboplatin counterparts with further increases following 49 addition of either STING agonist or PD-L1 ICB. However, despite the stronger ICD inducing 50 ability of doxorubicin, overall survival of mice treated with carboplatin + STING agonist + PD-51 L1 ICB was the longest. Findings from our pre-clinical study provide novel insights for 52 rationalized combinations of immune sensitizing agents such as STING pathway activators to 53 improve response of HGSC patients to chemotherapy and ICB in the primary and recurrent 54 settings. 55 56 57

show abstract

“…The role of immunotherapy drugs, particularly checkpoint inhibitors, is rapidly evolving in the management of RCC having shown a significant survival benefit in the treatment of metastatic disease [44] , [45] , [46] . Based on preclinical and clinical data, a particularly promising approach is the combination of RT and immunotherapy to augment the local efficacy of RT as well as to allow for improved and more durable systemic responses with immunotherapy [47] . In this context, RT plays an important role in the potentiation and modulation of tumor immunity.…”

Section: Combination Of Radiation Therapy and Immunotherapymentioning

confidence: 99%

Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer

Tselis

Chatzikonstantinou

2019

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Highlights Conventional fractionated radiotherapy (RT) is predominantly used for the palliation of symptomatic metastatic disease. Hypofractionated stereotactic RT is increasingly adopted for the treatment of locally recurrent and oligometastatic disease. High-dose radiation seems to have an immunogenic effect in patients with renal cell cancer. Combinations of ablative RT with immunotherapies are promising approaches that might improve outcomes.

show abstract

Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies

Cited by 31 publications

References 43 publications

Immune Cell Infiltration in Bladder Cancer

Immune Cell Infiltration in Bladder Cancer

Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer

Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer

Contact Info

Product

Resources

About